These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

591 related articles for article (PubMed ID: 29374318)

  • 1. Multicenter validation of cancer gene panel-based next-generation sequencing for translational research and molecular diagnostics.
    Hirsch B; Endris V; Lassmann S; Weichert W; Pfarr N; Schirmacher P; Kovaleva V; Werner M; Bonzheim I; Fend F; Sperveslage J; Kaulich K; Zacher A; Reifenberger G; Köhrer K; Stepanow S; Lerke S; Mayr T; Aust DE; Baretton G; Weidner S; Jung A; Kirchner T; Hansmann ML; Burbat L; von der Wall E; Dietel M; Hummel M
    Virchows Arch; 2018 Apr; 472(4):557-565. PubMed ID: 29374318
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Performance comparison of two commercial human whole-exome capture systems on formalin-fixed paraffin-embedded lung adenocarcinoma samples.
    Bonfiglio S; Vanni I; Rossella V; Truini A; Lazarevic D; Dal Bello MG; Alama A; Mora M; Rijavec E; Genova C; Cittaro D; Grossi F; Coco S
    BMC Cancer; 2016 Aug; 16(1):692. PubMed ID: 27578032
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validation of the Oncomine
    Williams HL; Walsh K; Diamond A; Oniscu A; Deans ZC
    Virchows Arch; 2018 Oct; 473(4):489-503. PubMed ID: 30105577
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted Next Generation Sequencing as a Reliable Diagnostic Assay for the Detection of Somatic Mutations in Tumours Using Minimal DNA Amounts from Formalin Fixed Paraffin Embedded Material.
    de Leng WW; Gadellaa-van Hooijdonk CG; Barendregt-Smouter FA; Koudijs MJ; Nijman I; Hinrichs JW; Cuppen E; van Lieshout S; Loberg RD; de Jonge M; Voest EE; de Weger RA; Steeghs N; Langenberg MH; Sleijfer S; Willems SM; Lolkema MP
    PLoS One; 2016; 11(2):e0149405. PubMed ID: 26919633
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Implementation of next generation sequencing technology for somatic mutation detection in routine laboratory practice.
    Giardina T; Robinson C; Grieu-Iacopetta F; Millward M; Iacopetta B; Spagnolo D; Amanuel B
    Pathology; 2018 Jun; 50(4):389-401. PubMed ID: 29752127
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amplicon-Based NGS Panels for Actionable Cancer Target Identification in Follicular Cell-Derived Thyroid Neoplasia.
    Madsen MB; Kiss K; Cilius Nielsen F; Bennedbæk FN; Rossing M
    Front Endocrinol (Lausanne); 2020; 11():146. PubMed ID: 32265839
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of cytocentrifugation supernatant fluid and formalin-fixed paraffin-embedded tissue for targeted next-generation sequencing.
    Janaki N; Harbhajanka A; Michael CW; Bomeisl P; Wasman J; Atchley M; Miskiewicz K; Alouani D; Sadri N
    Cancer Cytopathol; 2019 May; 127(5):297-305. PubMed ID: 30933438
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pre-clinical validation of a next generation sequencing testing panel.
    Lüsebrink J; Pieper M; Tillmann RL; Brockmann M; Schildgen O; Schildgen V
    Exp Mol Pathol; 2018 Jun; 104(3):170-174. PubMed ID: 29641993
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Robustness of Next Generation Sequencing on Older Formalin-Fixed Paraffin-Embedded Tissue.
    Carrick DM; Mehaffey MG; Sachs MC; Altekruse S; Camalier C; Chuaqui R; Cozen W; Das B; Hernandez BY; Lih CJ; Lynch CF; Makhlouf H; McGregor P; McShane LM; Phillips Rohan J; Walsh WD; Williams PM; Gillanders EM; Mechanic LE; Schully SD
    PLoS One; 2015; 10(7):e0127353. PubMed ID: 26222067
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-throughput detection of clinically targetable alterations using next-generation sequencing.
    Vendrell JA; Grand D; Rouquette I; Costes V; Icher S; Selves J; Larrieux M; Barbe A; Brousset P; Solassol J
    Oncotarget; 2017 Jun; 8(25):40345-40358. PubMed ID: 28404952
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Towards a Next-Generation Sequencing Diagnostic Service for Tumour Genotyping: A Comparison of Panels and Platforms.
    Burghel GJ; Hurst CD; Watson CM; Chambers PA; Dickinson H; Roberts P; Knowles MA
    Biomed Res Int; 2015; 2015():478017. PubMed ID: 26351634
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical next-generation sequencing in patients with non-small cell lung cancer.
    Hagemann IS; Devarakonda S; Lockwood CM; Spencer DH; Guebert K; Bredemeyer AJ; Al-Kateb H; Nguyen TT; Duncavage EJ; Cottrell CE; Kulkarni S; Nagarajan R; Seibert K; Baggstrom M; Waqar SN; Pfeifer JD; Morgensztern D; Govindan R
    Cancer; 2015 Feb; 121(4):631-9. PubMed ID: 25345567
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Performance validation of an amplicon-based targeted next-generation sequencing assay and mutation profiling of 648 Chinese colorectal cancer patients.
    Wang Y; Liu H; Hou Y; Zhou X; Liang L; Zhang Z; Shi H; Xu S; Hu P; Zheng Z; Liu R; Tang T; Ye F; Liang Z; Bu H
    Virchows Arch; 2018 Jun; 472(6):959-968. PubMed ID: 29705968
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development and validation of the JAX Cancer Treatment Profile™ for detection of clinically actionable mutations in solid tumors.
    Ananda G; Mockus S; Lundquist M; Spotlow V; Simons A; Mitchell T; Stafford G; Philip V; Stearns T; Srivastava A; Barter M; Rowe L; Malcolm J; Bult C; Karuturi RK; Rasmussen K; Hinerfeld D
    Exp Mol Pathol; 2015 Feb; 98(1):106-12. PubMed ID: 25562415
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of DNA integrity on the success rate of tissue-based next-generation sequencing: Lessons from nationwide cancer genome screening project SCRUM-Japan GI-SCREEN.
    Kuwata T; Wakabayashi M; Hatanaka Y; Morii E; Oda Y; Taguchi K; Noguchi M; Ishikawa Y; Nakajima T; Sekine S; Nomura S; Okamoto W; Fujii S; Yoshino T;
    Pathol Int; 2020 Dec; 70(12):932-942. PubMed ID: 33030786
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of the Ion AmpliSeq Cancer Hotspot Panel in clinical molecular pathology laboratories for analysis of solid tumours: With emphasis on validation with relevant single molecular pathology tests and the Oncomine Focus Assay.
    Lee A; Lee SH; Jung CK; Park G; Lee KY; Choi HJ; Min KO; Kim TJ; Lee EJ; Lee YS
    Pathol Res Pract; 2018 May; 214(5):713-719. PubMed ID: 29615338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytology smears as excellent starting material for next-generation sequencing-based molecular testing of patients with adenocarcinoma of the lung.
    Velizheva NP; Rechsteiner MP; Wong CE; Zhong Q; Rössle M; Bode B; Moch H; Soltermann A; Wild PJ; Tischler V
    Cancer Cytopathol; 2017 Jan; 125(1):30-40. PubMed ID: 27636102
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Versatile ion S5XL sequencer for targeted next generation sequencing of solid tumors in a clinical laboratory.
    Mehrotra M; Duose DY; Singh RR; Barkoh BA; Manekia J; Harmon MA; Patel KP; Routbort MJ; Medeiros LJ; Wistuba II; Luthra R
    PLoS One; 2017; 12(8):e0181968. PubMed ID: 28767674
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Comparison of different massive parallel sequencing platforms for mutation profiling in formalin-fixed and paraffin-embedded samples].
    Jiang RR; Wang YJ; Teng XD; Xiao L; Bu H; Ye F
    Zhonghua Bing Li Xue Za Zhi; 2018 Aug; 47(8):591-596. PubMed ID: 30107663
    [No Abstract]   [Full Text] [Related]  

  • 20. Comprehensive evaluation and validation of targeted next-generation sequencing performance in two clinical laboratories.
    Mendez P; Dang J; Kim JW; Lee S; Yoon JH; Kim T; Sailey CJ; Jablons DM; Kim IJ
    Int J Oncol; 2016 Jul; 49(1):235-42. PubMed ID: 27121194
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.